huntingtons-disease-like-1

Huntington's Disease-Like 1 (HDL1)

Overview

Huntington's disease-like 1 (HDL1) is a rare autosomal dominant neurodegenerative disorder characterized by a clinical phenotype that closely resembles Huntington's disease but is caused by mutations in the prion protein gene (PRNP). HDL1 was first described in 2001 and represents an important differential diagnosis for patients presenting with choreiform movements and cognitive decline when genetic testing for Huntington's disease is negative[@young1999]. The disease is classified as a genetic prion disease, specifically a "HDR" (Huntington's disease-like) syndrome, with mutations in the prion protein gene leading to a phenotype that mimics the classic triad of Huntington's disease: motor impairment (chorea), cognitive decline, and psychiatric disturbances[@singeltop1999].

Pathway / Mechanism Diagram

Huntington's Disease-Like 1 (HDL1)

Overview

Huntington's disease-like 1 (HDL1) is a rare autosomal dominant neurodegenerative disorder characterized by a clinical phenotype that closely resembles Huntington's disease but is caused by mutations in the prion protein gene (PRNP). HDL1 was first described in 2001 and represents an important differential diagnosis for patients presenting with choreiform movements and cognitive decline when genetic testing for Huntington's disease is negative[@young1999]. The disease is classified as a genetic prion disease, specifically a "HDR" (Huntington's disease-like) syndrome, with mutations in the prion protein gene leading to a phenotype that mimics the classic triad of Huntington's disease: motor impairment (chorea), cognitive decline, and psychiatric disturbances[@singeltop1999].

Pathway / Mechanism Diagram

Epidemiology

HDL1 is an extremely rare disorder, with only a limited number of families reported worldwide since its initial description. The disease appears to have equal sex distribution, consistent with autosomal dominant inheritance. Cases have been reported in various ethnic backgrounds, though the majority of documented cases come from European families. The prevalence is estimated to be less than 1 per million, making HDL1 one of the rarest neurodegenerative disorders. The disease typically presents in the third to sixth decade of life, similar to the typical age of onset in Huntington's disease[@nielsen2018].

Genetics and Pathophysiology

Genetic Basis

HDL1 is caused by insertions of octapeptide repeat sequences in the PRNP gene located on chromosome 20p12. The prion protein (PrP) is a glycosylphosphatidylinositol-anchored protein highly expressed in the central nervous system, particularly in neurons. The wild-type prion protein contains five octapeptide repeats in the N-terminal domain (PHGGGWGQ motif). Pathogenic mutations in HDL1 involve the insertion of additional copies of this octapeptide repeat unit, typically ranging from 1 to 9 extra repeats[@young1999].

The number of inserted repeats correlates with disease severity and age of onset:

• 1-4 extra repeats: Later onset, milder phenotype
• 5-7 extra repeats: Typical HDL1 presentation
• 8+ extra repeats: Earlier onset, more severe progression

Prion Protein Biology

The cellular prion protein (PrP^C) is a 253-amino acid glycoprotein anchored to the cell membrane via a GPI anchor. It is expressed predominantly in the central and peripheral nervous system, with high expression in the hippocampus, cerebral cortex, basal ganglia, and cerebellum. The physiological function of PrP^C remains incompletely understood but appears to involve:

• Copper ion binding and homeostasis
• Synaptic function and plasticity
• Neuronal protection against oxidative stress
• Cell signaling through various receptors
• Metal ion transport and regulation

Molecular Pathogenesis

The pathological mechanism in HDL1 involves the conversion of the normal cellular prion protein (PrP^C) to an abnormal conformer (PrP^Sc), leading to neurotoxicity and neurodegeneration. This conformational change results in:

• Increased beta-sheet content in the protein structure
• Aggregation and formation of amyloid fibrils
• Resistance to proteolytic degradation
• Accumulation as extracellular plaques
• Neuronal loss and spongiform changes[@colby2011]

Cellular Mechanisms of Neurodegeneration

Recent research has detailed several key pathways involved in prion protein-mediated neurotoxicity:

Endoplasmic Reticulum Stress: Mutant prion protein accumulates in the ER, triggering the unfolded protein response (UPR) and leading to neuronal apoptosis. The UPR activates three signaling branches: IRE1, PERK, and ATF6, all contributing to cell death pathways.

Mitochondrial Dysfunction: Prion protein mutations impair mitochondrial function through:

• Decreased mitochondrial membrane potential
• Reduced ATP production
• Increased mitochondrial permeability

Oxidative Stress: The prion protein normally participates in cellular antioxidant responses. Mutant forms lose this protective function, leading to:

• Increased lipid peroxidation
• Protein oxidation
• DNA damage
• Neuronal death[@cai2019]

• Interleukin-1 beta (IL-1β)
• Tumor necrosis factor-alpha (TNF-α)
• Interleukin-6 (IL-6)

Clinical Presentation

Patients with HDL1 present with features that are often indistinguishable from Huntington's disease, making differential diagnosis challenging.

Motor Symptoms

Chorea

• Non-rhythmic, purposeless movements
• Semi-purposeful appearance (patients may incorporate movements into voluntary acts)
• Variable intensity, worsening with stress and improving with sleep
• Progressive involvement of axial and proximal muscles
• Gait abnormalities as the disease progresses[@nielsen2018]

Dystonia

• Involuntary muscle contractions
• Abnormal postures (sustained twistings)
• Focal dystonia in cranial muscles
• Action dystonia during voluntary movement

Parkinsonism

• Bradykinesia (slowed movements)
• Rigidity (increased muscle tone)
• Postural instability
• Tremor (less common than in Parkinson's)
• Shuffling gait

Other Motor Features

• Dysarthria: Slurred, variable speech due to facial chorea
• Dysphagia: Difficulty swallowing, risk of aspiration
• Gait instability: Falls due to combined chorea and dystonia
• Ocular motor abnormalities: Saccadic slowing

Cognitive Symptoms

Cognitive decline follows a pattern similar to Huntington's disease, affecting multiple domains:

Executive Dysfunction

• Impaired planning and organization
• Reduced cognitive flexibility
• Difficulty with multitasking
• Poor judgment and decision-making
• Decreased verbal fluency

Memory Deficits

• Working memory impairment
• Difficulty with episodic recall
• Learning new information
• Spatial memory deficits

Psychomotor Changes

• Mental slowing (bradyphrenia)
• Reduced processing speed
• Decreased reaction time
• Attentional deficits

Language

• Word-finding difficulties
• Reduced verbal output
• Impaired comprehension of complex information
• Echolalia in advanced stages

Psychiatric Symptoms

Psychiatric disturbances are common and may precede motor symptoms by years:

Depression

• Depressed mood
• Anhedonia (loss of pleasure)
• Sleep disturbances
• Appetite changes
• Fatigue
• Suicidal ideation

Anxiety

• Generalized anxiety
• Panic attacks
• Social anxiety
• Anxiety related to chorea awareness

Psychosis

• Visual hallucinations (less common)
• Auditory hallucinations
• Delusions (paranoid themes)
• Thought disorders

Personality Changes

• Irritability
• Aggression
• Emotional lability
• Apathy
• Disinhibition

Behavior and Social Impact

The combination of motor, cognitive, and psychiatric symptoms creates significant social impact:

• Social withdrawal due to chorea and psychiatric symptoms
• Unemployment due to functional impairment
• Relationship difficulties
• Financial strain from care needs
• Reduced quality of life

Disease Course and Progression

Age of Onset

The typical age of onset ranges from 30 to 60 years, with a mean of approximately 45 years. There is an inverse correlation between the number of octapeptide repeats and age of onset[@nielsen2018]:

• 5 extra repeats: onset around 50-55 years
• 7 extra repeats: onset around 40-45 years
• 9+ extra repeats: onset in the third decade

Disease Progression

The disease progresses over 10-20 years through recognizably stages:

Early Stage (Years 1-5):

• Mild chorea, primarily facial and distal
• Minimal functional impairment
• Psychiatric symptoms (depression, anxiety)
• Subtle cognitive changes
• Preserved independence

• Chorea becomes generalized
• Cognitive decline notable
• Psychiatric symptoms prominent
• Gait instability begins
• Requires some assistance

• Severe motor impairment
• Marked cognitive decline
• Severe dysphagia
• Wheelchair or bed bound
• Total care dependence

Causes of Death

Common causes of mortality in HDL1:

• Aspiration pneumonia (due to dysphagia)
• Cachexia and malnutrition
• Infections (urinary tract, respiratory)
• Falls and trauma
• Suicide (especially in early stages)

Diagnosis

Clinical Assessment

The diagnostic workup involves:

Neurological Examination

• Assessment of chorea severity (quantified using standardized scales)
• Evaluation of cognitive function (MMSE, MoCA)
• Psychiatric assessment
• Assessment of functional abilities

Genetic Testing

• Negative HTT gene testing (CAG repeat < 36)
• PRNP gene sequencing identifying octapeptide repeat insertions
• Analysis of repeat number for prognostic information

Neuroimaging

MRI Brain:

• Caudate nucleus atrophy
• Putamen atrophy
• Cortical atrophy (particularly frontal)
• Ventricular enlargement
• White matter changes

• Hypometabolism in striatum
• Hypometabolism in frontal cortex
• Pattern similar to Huntington's disease

• Reduced fractional anisotropy in striatum
• White matter tract involvement

Additional Tests

• Cerebrospinal fluid (CSF): Typically normal; 14-3-3 protein may be elevated
• EEG: May show slowing in advanced stages

Differential Diagnosis

Distinguishing HDL1 from other conditions is critical:

Huntington's Disease

• Normal PRNP sequencing
• Expanded CAG repeat in HTT

Huntington's Disease-Like 2 (HDL2)

• JPH3 gene mutation
• Similar phenotype to HDL1
• More common in African populations

Benign Hereditary Chorea

• Earlier onset
• Non-progressive
• No cognitive decline

Spinocerebellar Ataxias

• Ataxia rather than chorea
• Eye movement abnormalities
• Specific genetic mutations

Neuroacanthocytosis

• Acanthocytes on blood smear
• Elevated creatine kinase
• Specific genetic mutations (VPS13A)

Drug-Induced Chorea

• History of dopamine-blocking drugs
• Resolution after drug cessation
• No genetic mutation

Biomarkers

Fluid Biomarkers

• Neurofilament light chain (NfL): Elevated in CSF and blood
• Tau protein: May be elevated
• 14-3-3 protein: Present in CSF
• Total tau: Marker of neuronal injury

Imaging Biomarkers

• Striatal glucose hypometabolism
• Caudate/putamen atrophy on MRI
• White matter integrity loss on DTI

Treatment

Current Therapeutic Approaches

There is currently no disease-modifying treatment for HDL1. Management is symptomatic and supportive.

Pharmacological Management

For Chorea:

• Tetrabenazine: Dopamine-depleting agent; reduces chorea (dose 12.5-100 mg/day in divided doses)
• Deutetrabenazine: Deuterated tetrabenazine; better side effect profile
• Valbenazine: Once-daily dosing; FDA-approved for Huntington's chorea
• Antipsychotics: Haloperidol, olanzapine, risperidone (caution for side effects)

• Depression: SSRIs (fluoxetine, sertraline, citalopram), SNRIs (venlafaxine)
• Anxiety: Buspirone, benzodiazepines (short-term use)
• Psychosis: Atypical antipsychotics (quetiapine, clozapine)
• Irritability: Mood stabilizers (valproate, lamotrigine)

• No effective pharmacological treatments
• Avoid anticholinergic medications
• Monitor for drug-induced cognitive impairment

Non-Pharmacological Interventions

Physical Therapy:

• Maintain mobility
• Prevent contractures
• Fall prevention strategies
• Exercise programs

• Home safety assessments
• Assistive device recommendations
• Functional adaptation

• Dysarthria management
• Swallowing assessment and strategies
• Communication aids

• Dietary modification for dysphagia
• Weight monitoring
• Vitamin supplementation

• Patient and family counseling
• Support groups
• Cognitive behavioral therapy

Experimental Approaches

Disease-Modifying Therapies

Prion Protein-Targeting Approaches:

Prion Protein Knockdown:

• Antisense oligonucleotides (ASOs)
• RNA interference (RNAi)
• Small interfering RNAs (siRNAs)

• Anti-PrP monoclonal antibodies
• Passive immunization approaches

• Compounds targeting PrP^Sc formation
• Aggregation inhibitors

• Approaches to enhance clearance

Symptomatic Therapies Under Investigation

Chorea Management:

• Novel VMAT2 inhibitors
• Glycine transport inhibitors

• Antioxidant therapies
• Mitochondrial protectants
• Anti-apoptotic agents

• symptomatic cognitive enhancers (limited efficacy)[@masullo2019]

Animal Models

Several animal models have been developed to study HDL1:

Transgenic Mouse Models

• PrP-84dup: Mouse model with 84-base pair octapeptide repeat insertion
• PrP-96dup: Model with 96-base pair insertion
• PrP-Octapeptide Insertion Lines: Multiple lines with varying repeat sizes

Model Phenotypes

• Ataxia
• Motor dysfunction
• Cognitive deficits
• Prion protein deposition
• Spongiform changes

Therapeutic Testing

• Prion protein-lowering approaches
• Aggregation inhibitors
• Neuroprotective agents
• Immunotherapies[@sanders2016]

Research Directions

Current Research Focus

• Mechanisms of prion protein-mediated neurotoxicity
• Role of specific protein domains
• Interaction with cellular partners

• Early detection markers
• Disease progression markers
• Treatment response markers

• Prion protein-targeting drugs
• Gene therapy approaches
• Cell-based therapies

• Disease progression patterns
• Genotype-phenotype correlations
• Biomarker correlations

Clinical Trials

No clinical trials specifically for HDL1 have been completed. However, therapies developed for other prion diseases (including Creutzfeldt-Jakob disease) may be applicable:

• Antisense oligonucleotide therapies
• Antibody therapies
• Small molecule inhibitors

Relationship to Other Neurodegenerative Diseases

Prion Diseases Spectrum

HDL1 is part of the spectrum of human prion diseases:

Inherited Prion Diseases

• Gerstmann-Sträussler-Scheinker syndrome (GSS): Typically ataxic presentation
• Fatal familial insomnia (FFI): Sleep disruption as primary symptom
• Creutzfeldt-Jakob disease (CJD): Rapidly progressive dementia
• Variably protease-sensitive prionopathy (VPSPr): Novel phenotype

Sporadic Prion Diseases

• Sporadic CJD: Most common prion disease
• Sporadic fatal insomnia

Acquired Prion Diseases

• Variant CJD: BSE-associated
• Iatrogenic CJD: Infection-related

Overlap with Other Neurodegenerative Diseases

Prion protein dysfunction is increasingly recognized in other conditions:

Alzheimer's Disease:

• PrP interacts with amyloid-beta
• May modulate toxicity
• Potential therapeutic implications

• PrP in dopaminergic neurons
• Alpha-synuclein interactions

• Similar clinical phenotype
• Overlapping pathogenic mechanisms

Neuropathology

Gross Pathology

Postmortem examination reveals:

• Cortical atrophy (particularly frontal)
• Striatal atrophy (caudate and putamen)
• Ventricular enlargement
• Thalamic involvement

Microscopic Pathology

Spongiform Changes:

• Vacuolation throughout gray matter
• Most prominent in cerebral cortex
• Basal ganglia involvement
• Cerebellar changes

• Extracellular amyloid plaques (in some cases)
• Synaptic PrP deposition
• Perivacuolar pattern
• Astrocytic gliosis around deposits

• Cortical neurons
• Striatal neurons
• Cerebellar neurons
• Specific vulnerable populations

• Astrocytosis (GFAP positive)
• Microglial activation
• Present throughout affected regions

• Neurofibrillary tangles (variable)
• Amyloid angiopathy (some cases)

Prognosis and Quality of Life

Prognostic Factors

Negative Prognostic Factors:

• Early age of onset
• Large number of repeats
• Rapid progression of symptoms
• Early cognitive impairment
• Early psychiatric symptoms

• Later age of onset
• Smaller repeat insertions
• Slower progression
• Good response to symptomatic treatment

Quality of Life Considerations

Managing quality of life involves:

• Early diagnosis and counseling
• Symptomatic treatment optimization
• Supportive care services
• Caregiver support
• Advance care planning
• Palliative care integration

Conclusion

Huntington's disease-like 1 (HDL1) represents an important differential diagnosis for patients with Huntington's disease phenotype. Caused by octapeptide repeat insertions in the PRNP gene, this rare disorder shares clinical features with Huntington's disease while having distinct pathogenic mechanisms related to prion protein misfolding. Although no disease-modifying treatments exist, ongoing research into prion protein biology and therapeutic approaches offers hope for future interventions. Accurate diagnosis is critical for genetic counseling, prognostic planning, and potential enrollment in clinical trials as new therapies emerge. The relationship between HDL1 and other prion diseases, as well as the broader spectrum of neurodegenerative disorders, continues to provide insights into disease mechanisms and potential therapeutic targets[@puoti2020].

See Also

• [Huntington's Disease](/diseases/huntingtons)
• [Huntington's Disease-Like 2](/diseases/huntingtons-disease-like-2)
• [Prion Diseases](/mechanisms/prion-diseases)
• [Neuroacanthocytosis](/diseases/neuroacanthocytosis)
• [Creutzfeldt-Jakob Disease](/diseases/creutzfeldt-jakob-disease)
• [Gerstmann-Sträussler-Scheinker Syndrome](/diseases/gerstmann-straussler-scheinker)
• [PRNP Gene](/genes/prnp)

References